Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

First Posted Date
2021-05-18
Last Posted Date
2021-05-18
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
622
Registration Number
NCT04890522
Locations
🇨🇳

Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

First Posted Date
2021-05-11
Last Posted Date
2024-10-04
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT04882241
Locations
🇨🇳

Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638), Bengbu, Anhui, China

🇨🇳

Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 0647), Xi'an, Shaanxi, China

🇨🇳

Beijing Friendship Hospital ( Site 0637), Beijing, Beijing, China

and more 17 locations

No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer

First Posted Date
2021-04-28
Last Posted Date
2023-11-22
Lead Sponsor
Servicio de Salud Metropolitano Sur Oriente
Target Recruit Count
73
Registration Number
NCT04864067
Locations
🇨🇱

Complejo Asistencial Doctor Sótero del Rio, Santiago, RM, Chile

🇨🇱

Hospital Padre Hurtado, Santiago, RM, Chile

🇨🇱

Hospital La Florida, Santiago, RM, Chile

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

First Posted Date
2021-04-26
Last Posted Date
2021-12-16
Lead Sponsor
Merck Sharp & Dohme LLC
Registration Number
NCT04859582
Locations
🇨🇳

Peking Union Medical College Hospital ( Site 2425), Beijing, Beijing, China

🇨🇳

Fujian Medical University Union Hospital ( Site 2410), Fuzhou, Fujian, China

🇨🇳

900 Hospital of the Joint ( Site 2418), Fuzhou, Fujian, China

and more 25 locations

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

First Posted Date
2021-04-22
Last Posted Date
2024-10-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
193
Registration Number
NCT04854499
Locations
🇺🇸

UCLA Hematology/Oncology, Los Angeles, California, United States

🇺🇸

Memorial Healthcare System, Hollywood, Florida, United States

🇧🇪

Algemeen Ziekenhuis Klina, Brasschaat, Belgium

and more 84 locations

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

First Posted Date
2021-04-15
Last Posted Date
2024-12-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT04847063
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction

First Posted Date
2021-04-09
Last Posted Date
2024-03-18
Lead Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Target Recruit Count
79
Registration Number
NCT04840264
Locations
🇨🇳

The Sixth Affiliated hosipital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

First Posted Date
2021-03-29
Last Posted Date
2024-03-13
Lead Sponsor
Flemming Forsberg
Target Recruit Count
120
Registration Number
NCT04821284
Locations
🇳🇴

Haukeland University Hospital, Bergen, Norway

🇺🇸

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars

Not Applicable
Completed
Conditions
Scar Keloid
Interventions
Drug: 5-Fluorouracil
First Posted Date
2021-03-23
Last Posted Date
2022-04-07
Lead Sponsor
B.P. Koirala Institute of Health Sciences
Target Recruit Count
66
Registration Number
NCT04812626
Locations
🇳🇵

B.P. Koirala Institute of Health Sciences, Dharān Bāzār, Province No. 1, Nepal

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

First Posted Date
2021-03-02
Last Posted Date
2021-09-16
Lead Sponsor
Azienda Unità Sanitaria Locale Reggio Emilia
Target Recruit Count
280
Registration Number
NCT04776655
Locations
🇮🇹

Azienda ULSS 3 Serenissima, Mirano, VE, Italy

🇮🇹

Ospedale Civile di Guastalla, Guastalla, Reggio Emilia, Italy

🇮🇹

Ospedale San Salvatore, Coppito, L'Aquila, Italy

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy